VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform for Solid Tumor Therapies

VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.

Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. His experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development, according to VERAXA.

The appointment comes as VERAXA focuses on its BiTAC (bispecific T-cell engager) platform, which is designed to redirect T-cells to kill tumor cells. The company also develops bispecific antibody-drug conjugates (ADCs) and other innovative formats. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

For more details, visit the full press release at https://nnw.fm/cR1RS. The latest news and updates relating to VRXA are available in the company’s newsroom at http://nnw.fm/VRXA.